Antidepressant success in Phase III cheers Forest and Pierre Fabre
This article was originally published in Scrip
Executive Summary
Forest Laboratories and Pierre Fabre Medicament have reported positive preliminary top-line Phase III results for levomilnacipran for the treatment of adults with major depressive disorder (MDD).